AR080584A1 - Formas cristalinas hidratadas de n-(3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi) fenil]-n'- (4-fluorofenil) ciclopropano-1,1-dicarboxiamida - Google Patents
Formas cristalinas hidratadas de n-(3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi) fenil]-n'- (4-fluorofenil) ciclopropano-1,1-dicarboxiamidaInfo
- Publication number
- AR080584A1 AR080584A1 ARP110100801A ARP110100801A AR080584A1 AR 080584 A1 AR080584 A1 AR 080584A1 AR P110100801 A ARP110100801 A AR P110100801A AR P110100801 A ARP110100801 A AR P110100801A AR 080584 A1 AR080584 A1 AR 080584A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxy
- quinolin
- fluorophenyl
- fluoro
- phenyl
- Prior art date
Links
- -1 4-FLUOROPHENYL Chemical class 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 238000001237 Raman spectrum Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 abstract 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000036571 hydration Effects 0.000 abstract 1
- 238000006703 hydration reaction Methods 0.000 abstract 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31319210P | 2010-03-12 | 2010-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080584A1 true AR080584A1 (es) | 2012-04-18 |
Family
ID=43875241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100801A AR080584A1 (es) | 2010-03-12 | 2011-03-14 | Formas cristalinas hidratadas de n-(3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi) fenil]-n'- (4-fluorofenil) ciclopropano-1,1-dicarboxiamida |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130143881A1 (enExample) |
| EP (1) | EP2545038A1 (enExample) |
| JP (1) | JP2013522232A (enExample) |
| KR (1) | KR20130038206A (enExample) |
| CN (1) | CN102933551A (enExample) |
| AR (1) | AR080584A1 (enExample) |
| AU (1) | AU2011224203A1 (enExample) |
| CA (1) | CA2792852A1 (enExample) |
| EA (1) | EA201290906A1 (enExample) |
| MX (1) | MX2012010506A (enExample) |
| SG (1) | SG184040A1 (enExample) |
| TW (1) | TW201202228A (enExample) |
| WO (1) | WO2011112896A1 (enExample) |
| ZA (1) | ZA201206679B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| IL224189A (en) | 2010-07-16 | 2017-07-31 | Exelixis Inc | C-met modulator pharmaceutical compositions |
| JP6158705B2 (ja) | 2010-09-27 | 2017-07-05 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| KR20210147117A (ko) | 2011-02-10 | 2021-12-06 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| GEP201706678B (en) | 2011-05-02 | 2017-06-12 | Exelixis Inc | Method of treating cancer and bone cancer |
| CA2848512A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
| MX343288B (es) | 2011-10-20 | 2016-11-01 | Exelixis Inc | Proceso para la preparación de derivados de quinolina. |
| EP2844254A1 (en) | 2012-05-02 | 2015-03-11 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| BR112015023109A2 (pt) | 2013-03-15 | 2018-05-15 | Exelixis Inc | Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida |
| ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| UA123534C2 (uk) | 2014-02-14 | 2021-04-21 | Екселіксис, Інк. | Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування |
| JP6666849B2 (ja) | 2014-03-17 | 2020-03-18 | エグゼリクシス， インコーポレイテッド | カボザンチニブ製剤の投与 |
| CN106715397B (zh) | 2014-07-31 | 2021-07-23 | 埃克塞里艾克西斯公司 | 制备氟-18标记的卡博替尼及其类似物的方法 |
| AU2015301097B2 (en) | 2014-08-05 | 2021-03-04 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
| CN109069499A (zh) | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法 |
| KR20190018643A (ko) | 2016-05-16 | 2019-02-25 | 풀마젠 테라퓨틱스 (애즈마) 리미티드 | 퀴놀린 유도체의 결정 |
| CN116808044A (zh) | 2018-06-15 | 2023-09-29 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| KR20250136810A (ko) | 2023-01-31 | 2025-09-16 | 한다 온콜로지, 엘엘씨 | 개선된 카보잔티닙 조성물 및 사용 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2436888T3 (es) * | 2003-09-26 | 2014-01-07 | Exelixis, Inc | Moduladores c-Met y métodos de uso |
| TW201118072A (en) * | 2009-07-17 | 2011-06-01 | Exelixis Inc | Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
-
2011
- 2011-03-11 JP JP2012557269A patent/JP2013522232A/ja active Pending
- 2011-03-11 CA CA2792852A patent/CA2792852A1/en not_active Abandoned
- 2011-03-11 EP EP11709589A patent/EP2545038A1/en not_active Withdrawn
- 2011-03-11 EA EA201290906A patent/EA201290906A1/ru unknown
- 2011-03-11 SG SG2012067732A patent/SG184040A1/en unknown
- 2011-03-11 US US13/634,275 patent/US20130143881A1/en not_active Abandoned
- 2011-03-11 MX MX2012010506A patent/MX2012010506A/es not_active Application Discontinuation
- 2011-03-11 AU AU2011224203A patent/AU2011224203A1/en not_active Abandoned
- 2011-03-11 WO PCT/US2011/028035 patent/WO2011112896A1/en not_active Ceased
- 2011-03-11 TW TW100108394A patent/TW201202228A/zh unknown
- 2011-03-11 KR KR1020127025322A patent/KR20130038206A/ko not_active Withdrawn
- 2011-03-11 CN CN2011800137314A patent/CN102933551A/zh active Pending
- 2011-03-14 AR ARP110100801A patent/AR080584A1/es unknown
-
2012
- 2012-09-06 ZA ZA2012/06679A patent/ZA201206679B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130038206A (ko) | 2013-04-17 |
| WO2011112896A1 (en) | 2011-09-15 |
| AU2011224203A1 (en) | 2012-10-04 |
| TW201202228A (en) | 2012-01-16 |
| EA201290906A1 (ru) | 2013-03-29 |
| CA2792852A1 (en) | 2011-09-15 |
| US20130143881A1 (en) | 2013-06-06 |
| JP2013522232A (ja) | 2013-06-13 |
| SG184040A1 (en) | 2012-10-30 |
| EP2545038A1 (en) | 2013-01-16 |
| MX2012010506A (es) | 2012-10-15 |
| ZA201206679B (en) | 2013-05-29 |
| CN102933551A (zh) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080584A1 (es) | Formas cristalinas hidratadas de n-(3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi) fenil]-n'- (4-fluorofenil) ciclopropano-1,1-dicarboxiamida | |
| MX2012000809A (es) | Formas cristalinas de n-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin- 4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclop ropan-1,1-dicarboxamida. | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| ME02655B (me) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| HRP20110807T1 (hr) | Supstituirani pirimidodiazepini korisni kao plk1 inhibitori | |
| AR086242A1 (es) | Procedimiento de tratar el dolor por cancer y cancer de huesos | |
| NZ710133A (en) | Ingenol-3-acylates iii and ingenol-3-carbamates | |
| RU2014107486A (ru) | Бициклические пиримидоновые соединения | |
| NZ603454A (en) | Indoles useful for treating cellular proliferation diseases such as cancer | |
| BR112013002914A2 (pt) | promotores de apoptose de n-acilsulfonamida | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| BR112015003380A2 (pt) | composto de pirazolopirimidina | |
| MD20140023A2 (ro) | Derivaţi de pirolpirimidină şi purină | |
| PL2387563T5 (pl) | Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| EA201490419A1 (ru) | Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| MX338114B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| IN2015DN01119A (enExample) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| MX2014002112A (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| EA201290872A1 (ru) | Способ получения бензоксаборолов | |
| MX390763B (es) | Compuestos de tetraciclina | |
| NZ707366A (en) | Novel histone deacetylase inhibitors and their use in therapy | |
| PH12015502684A1 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |